Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: Results from the Angina Prognosis Study in Stockholm

Circulation

Volumn 95, Issue 10, 1997, Pages 2380-2386

  Held, Claes ^a   Hjemdahl, Paul ^b   Rehnqvist, Nina ^c   Wallén, N Håkan ^b   Björkander, Inge ^a   Eriksson, Sven V ^a   Forslund, Lennart ^a   Wiman, Björn ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

angina; fibrinolysis; plasminogen activators; prognosis

Indexed keywords

METOPROLOL; TISSUE PLASMINOGEN ACTIVATOR; VERAPAMIL;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0030997690     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.10.2380     Document Type: Article

References (29)

1. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis. 1994;8(suppl 1):253-262.
2. Johnson O, Mellbring G, Nilsson T. Defective fibrinolysis in survivors of myocardial infarction. Int J Cardiol. 1984;6:380-382.
3. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
4. Olofsson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77-82.
5. Francis RB, Kawanishi D, Baruch T, Mahrer P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J. 1988;115:776-780.
6. Aznar J, Estellés A, Tormo O, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535-541.
7. Held C, Hjemdahl P, Rehnqvist N, Wallén NH, Forslund L, Björkander I, Angelin B, Wiman B. Hemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS): a comparison with healthy controls. J Intent Med. 1997;241:59-69.
8. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
9. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
10. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Stud Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332:635-641.
11. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality to patients with coronary artery disease: a 7-year follow-up. Circulation. 1993;88:2030-2034.
12. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and β-adrenergic receptor blockers. J Cardiovasc Pharmacol. 1991;18(suppl 9):S41-S44.
13. Teger-Nilsson AC, Larsson PT, Hjemdahl P, Olsson G. Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease: potential effects of β-blockade. Circulation. 1991;84(suppl VI):VI-72-VI-77.
14. Rehnqvist N, Hjemdahl P, Billing E, Björkander I, Eriksson SV, Forslund L, Held C, Näsman P, Wallén NH. Effects of metoprolol vs verapamil in patients with stable angina pectoris: the Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1990;17:76-81.
15. Hjemdahl P, Eriksson SV, Held C, Rehnqvist N. Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol. 1996;77:6D-15D.
16. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its 'fast' inhibitor in plasma. Clin Chem. 1986;32/3:482-485.
17. SAS Institute Inc. SAS/STAT Version 6. 4th ed. Cary, NC: SAS Institute; 1989.
18. Billing E, Hjemdahl P, Rehnqvist N. Psychosocial variables in female versus male patients with stable angina pectoris and matched healthy controls. Eur Heart J. In press.
19. Benchimol D, Dartigues JF, Benchimol H, Drouillet F, Lauribe P, Marazanof M, Couffinhal T, Bonnet J. Predictive value of hemostatic factors for sudden death in patients with stable angina pectoris. Am J Cardiol. 1995;76:241-244.
20. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
21. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
22. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb. 1993;13:1412-1417.
23. Andreotti F, Davies GJ, Hackett DR, Kahn MI, De Bart ACW, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol. 1988;62:635-637.
24. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE, for the Determinants of Myocardial Infarction Onset Study Investigators. Triggering of acute myocardial infarction by heavy physical exertion: protection against triggering by regular exertion. N Engl J Med. 1993;329:1677-1683.
25. Willich SN, Lewis M, Löwel H, Arntz HR, Schubert F, Schröder R, for the Triggers and Mechanisms of Myocardial Infarction Study Group. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med. 1993;329:1684-1690.
26. Teger-Nilsson AC, Dahlöf C, Haglund E, Hedman C, Olsson G, Âblad B. Influence of metoprolol CR/ZOK on plasminogen activator inhibitor (PAI-1) in man: a pilot study. J Clin Pharmacol. 1990;30:S132-S137.
27. Landin K, Tengborn L, Smith U. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man. Thromb Haemost. 1994;71:783-787.
28. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost. 1990;63:482-487.
29. Wright RA, Perrie AM, Stenhouse F, Alberti KGMM, Riemersma RA, MacGregor IR, Boon NA. The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. Eur J Clin Pharmacol. 1994;46:279-282.